Dergiler / Klinik Psikofarmakoloji Bülteni / 2016 / Cilt: 26 - Sayı: 2

Determination of CYP2C19 Polymorphism, Side Effects, and Medication Adherence in Patients Who have Utilized Selective Serotonin Reuptake Inhibitors

Sayfa
152–160
Yayın Tarihi
2022-10-17
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Another interesting finding is the high rate of ultrarapid metabolizers of CYP2C19

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Objective: The aim of this study is to determine relationship of cytochrome P-450 2C19 (CYP2C19) enzymes polymorphism, side effects, and medication adherence in patients who have been diagnosed with major depression and have utilized selective serotonin reuptake inhibitors.
📊
Temel Bulgular & Veri:Methods: Fifty-three major depression patients (mean of age: 33.25±11.29 years old; male/female: 7/46) were included in this study.
💡
Sonuç & Katkı:Another interesting finding is the high rate of ultrarapid metabolizers of CYP2C19
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Abstract

Objective: The aim of this study is to determine relationship of cytochrome P-450 2C19 (CYP2C19) enzymes polymorphism, side effects, and medication adherence in patients who have been diagnosed with major depression and have utilized selective serotonin reuptake inhibitors. Methods: Fifty-three major depression patients (mean of age: 33.25±11.29 years old; male/female: 7/46) were included in this study. Polymorphisms were determined from genomic DNA by using the 'Real-Time Polymerase Chain Reaction' method. Side effects and medication adherence levels were assessed by using the 'Toronto Side Effects Scale' and the four items medication adherence scale (Morisky, Green and Levine), respectively. Results: The most common side effects that patients reported were drowsiness/daytime somnolence (54.7%), malaise or fatigue (43.4%), sweating (43.4%), nausea (41.5%) and dry mouth (41.5%). Only nine (17%) patients were found to be highly adherent to their medication. When evaluating the CYP2C19 polymorphisms of patients, 37.7%, 24.5% and 20.8% of the patients were classified as intermediate, extensive and ultra-rapid metabolizers, respectively. Allele frequencies of CYP2C19*17 and CYP2C19*2 was calculated as 24.5% and 27.4%, respectively. Although there were some differences in side effect scores and medication adherences among the polymorphism groups, these relationships were not found to be statistically significant. Conclusion: This study shows that patients who utilized antidepressants frequently experienced side effects and had low medication adherence. Another interesting finding is the high rate of ultrarapid metabolizers of CYP2C19

🔖

Bu Makaleye Atıf Yap

DENİZ, S., SANCAR, M., OKUYAN, B., ATA, P., OZAKPİNAR, O. B., TALAS, A., GUNES, T., CALİSKAN, M., IZZETTİN, F. V. (2022). Determination of CYP2C19 Polymorphism, Side Effects, and Medication Adherence in Patients Who have Utilized Selective Serotonin Reuptake Inhibitors. Klinik Psikofarmakoloji Bülteni, Cilt: 26 - Sayı: 2, 152–160. https://ajindex.com/articles/573877

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (12)

  1. Porcelli S, Fabbri C, Serretti A. Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with antidepressant efficacy. Eur Neuropsychopharmacol 2012
  2. 22(4):239-58. [CrossRef] 2. Johnston JA, Lineberry CG, Ascher JA, Davidson J, Khayrallah MA, Feighner JP, et al. A 102-center prospective study of seizure in association with bupropion. J Clin Psychiatry 1991
  3. 52(11):450-6. 3. Ingelman-Sundberg M, Sim SC, Gomez A, RodriguezAntona C. Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol Ther 2007
  4. 116(3):496-526. [CrossRef] 4. Porcelli S, Fabbri C, Drago A, Gibiino S, De Ronchi D, Serretti A. Genetics and antidepressants: Where we are. Clin Neuropsychiatry 2011
  5. 8(2):99-150. 5. Lee IS, Kim D. Polymorphic metabolism by functional alterations of human cytochrome P450 enzymes. Arch Pharm Res 2011
  6. 34(11):1799-816. [CrossRef] 6. Kobayashi K, Ishizuka T, Shimada N, Yoshimura Y, Kamijima K, Chiba K. Sertraline N-demethylation is catalyzed by multiple isoforms of human cytochrome P-450 in vitro. Drug Metab Dispos 1999
  7. 27(7):763-6. 7. Obach RS, Cox LM, Tremaine LM. Sertraline is metabolized by multiple cytochrome P450 enzymes, monoamine oxidases, and glucuronyl transferases in human: an in vitro study. Drug Metab Dispos 2005
  8. 33(2):262-70. [CrossRef] 8. Xu ZH, Wang W, Zhao XJ, Huang SL, Zhu B, He N, et al. Evidence for involvement of polymorphic CYP2C19 and 2C9 in the N-demethylation of sertraline in human liver microsomes. Br J Clin Pharmacol 1999
  9. 48(3):416-23. [CrossRef] 9. Kobayashi K, Chiba K, Yagi T, Shimada N, Taniguchi T, Horie T, et al. Identification of cytochrome P450 isoforms involved in citalopram N-demethylation by human liver microsomes. J Pharmacol Exp Ther 1997
  10. 280(2):927-33. 10. Rochat B, Amey M, Gillet M, Meyer UA, Baumann P. Identification of three cytochrome P450 isozymes involved in N-demethylation of citalopram enantiomers in human liver microsomes. Pharmacogenetics 1997
  11. 7(1):1-10. [CrossRef] 11. Grasmäder K, Verwohlt PL, Rietschel M, Dragicevic A, Müller M, Hiemke C, et al. Impact of polymorphisms of cytochrome-P450 isoenzymes 2C9, 2C19 and 2D6 on plasma concentrations and clinical effects of antidepressants in a naturalistic clinical setting. Eur J Clin Pharmacol 2004
  12. 60(5):329-36. [CrossRef] 12. Meyer UA, Amrein R, Balant LP, Bertilsson L, Eichelbaum M, Guentert TW, et al. Antidepressants and drug-metabolizing enzymes--expert group report